Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Fighting HIV with antibodies

09.04.2015

30 years after HIV was discovered to be the cause of the acquired immune deficiency syndrome (AIDS), and despite intensive research, no vaccine or cure has yet been found. 

An international team of scientists, in collaboration with the German Center for Infection Research (DZIF) and the University Hospital of Cologne, has now tested a new generation of antibodies in humans for the first time. They have demonstrated that these broadly neutralising antibodies significantly reduce the number of human immunodeficiency viruses (HIV) in infected patients’ blood. The results have been published in the renowned journal Nature.


Fighting HIV with Antibodies

Zach Veilleux, Rockefeller University

Today, HIV infections can be well controlled with a combination of different antiviral drugs. However, the drugs can cause some severe side effects, are expensive and have to be taken over a lifetime. Additionally, resistance can develop, which challenges individual treatment. “This is why we still need new treatment options,” explains Cologne infectious diseases specialist Prof Gerd Fätkenheuer, who is researching new ways of treating and preventing AIDS at the German Center for Infection Research.

In the trial, published today in Nature, doctors from the University Hospital of Cologne together with researchers of Michel Nussenzweig’s Laboratory from Rockefeller University in New York (USA) investigated a new treatment approach. For the first time, the scientists conducted human trials with an antibody (3BNC117), which was developed previously in Nussenzweig laboratory.

The special thing about this antibody is its ability to neutralise a large number of different human immunodeficiency viruses effectively. In the trial, which was co-funded by the DZIF, the antibody showed good tolerability and favourable pharmacological properties.

Furthermore, patients undergoing treatment at the highest dose level (30 mg per kg of bodyweight) showed a significant drop in viral load. “With this, the antibody has a potency comparable to the drugs we are currently using for treatment,” Fätkenheuer explains. The treatment effects could be observed for up to 28 days after administration of the antibodies.

The trial consequently opens up a new field in HIV treatment. Co-First Author Prof Florian Klein, who will soon be changing from the Rockefeller University to the University Hospital of Cologne, sees particular potential in the mechanism of action of broadly neutralising antibodies: “Neutralising antibodies have a different mechanism of action and different pharmacological properties compared to the HIV drugs that have been used up to now.”

According to the scientists, “Neutralising antibodies could play an important role in HIV treatment and HIV prevention.” Plans for clinical trials investigating the efficacy of broadly neutralising antibodies with regard to curing HIV are currently underway.

Current publication
Caskey, M.*; Klein, F.*(*Co-First Authors); Lorenzi, J.C.C.; Seaman, M.S.; West, A.P., Jr, Buckley, N.; Kremer, G.; Nogueira, L.; Braunschweig, M.; Scheid, J.F.; Horwitz, J. A.; Shimeliovich, I.; Avraham-Shulman, S.B.; Witmer-Pack, M.; Platten, M., Lehmann, C.; Burke, L.A.; Hawthorne, T.; Gorelick, R.J.; Walker, B.D.; Keler, T.; Gulick, R.M., Fätkenheuer, G.; Schlesinger, S.J.; Nussenzweig, M.C.:
Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117
Nature, online first released on April 08 (2015)
DOI: 10.1038/nature14411

Contact
Prof Gerd Fätkenheuer
E-mail: g.faetkenheuer@uni-koeln.de

Prof Florian Klein
T +12123278367 /Mobile +17182900235
E-mail: fklein@rockefeller.edu

DZIF Press Office
Karola Neubert and Janna Schmidt
T +49531-6181-1170/1154
E-mail: presse@dzif.de

Press Office University Hospital of Cologne
Christoph Wanko
T +49221-478-88757
E-mail: Christoph.wanko@uk-koeln.de

Karola Neubert | idw - Informationsdienst Wissenschaft
Further information:
http://www.uk-koeln.de/

More articles from Health and Medicine:

nachricht Purdue cancer identity technology makes it easier to find a tumor's 'address'
16.11.2018 | Purdue University

nachricht Microgel powder fights infection and helps wounds heal
14.11.2018 | Michigan Technological University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: UNH scientists help provide first-ever views of elusive energy explosion

Researchers at the University of New Hampshire have captured a difficult-to-view singular event involving "magnetic reconnection"--the process by which sparse particles and energy around Earth collide producing a quick but mighty explosion--in the Earth's magnetotail, the magnetic environment that trails behind the planet.

Magnetic reconnection has remained a bit of a mystery to scientists. They know it exists and have documented the effects that the energy explosions can...

Im Focus: A Chip with Blood Vessels

Biochips have been developed at TU Wien (Vienna), on which tissue can be produced and examined. This allows supplying the tissue with different substances in a very controlled way.

Cultivating human cells in the Petri dish is not a big challenge today. Producing artificial tissue, however, permeated by fine blood vessels, is a much more...

Im Focus: A Leap Into Quantum Technology

Faster and secure data communication: This is the goal of a new joint project involving physicists from the University of Würzburg. The German Federal Ministry of Education and Research funds the project with 14.8 million euro.

In our digital world data security and secure communication are becoming more and more important. Quantum communication is a promising approach to achieve...

Im Focus: Research icebreaker Polarstern begins the Antarctic season

What does it look like below the ice shelf of the calved massive iceberg A68?

On Saturday, 10 November 2018, the research icebreaker Polarstern will leave its homeport of Bremerhaven, bound for Cape Town, South Africa.

Im Focus: Penn engineers develop ultrathin, ultralight 'nanocardboard'

When choosing materials to make something, trade-offs need to be made between a host of properties, such as thickness, stiffness and weight. Depending on the application in question, finding just the right balance is the difference between success and failure

Now, a team of Penn Engineers has demonstrated a new material they call "nanocardboard," an ultrathin equivalent of corrugated paper cardboard. A square...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

“3rd Conference on Laser Polishing – LaP 2018” Attracts International Experts and Users

09.11.2018 | Event News

On the brain’s ability to find the right direction

06.11.2018 | Event News

European Space Talks: Weltraumschrott – eine Gefahr für die Gesellschaft?

23.10.2018 | Event News

 
Latest News

Purdue cancer identity technology makes it easier to find a tumor's 'address'

16.11.2018 | Health and Medicine

Good preparation is half the digestion

16.11.2018 | Life Sciences

Microscope measures muscle weakness

16.11.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>